NCT02662972View on ClinicalTrials.gov

Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Trigeminal NeuralgiaHeadache Disorders
Interventions
DRUG

Botulinum Toxin Type A

Trial Locations (1)

Unknown

Department of Neuroscience, Norwegian University of Science and Technology, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT02662972 - Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues. | Biotech Hunter | Biotech Hunter